Clinicopathological and molecular features of the gastrointestinal stromal tumor

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 5, 2011, Pages 715-721

  Sugai, Tamotsu ^a   Uesugi, Noriyuki ^a   Yamada, Noriyuki ^a   Takahashi, Keisuke ^a   Wakabayashi, Go ^a   Terashima, Masanori ^b   Chiba, Toshimi ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

Author keywords

c kit; CD34; GIST

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; SUNITINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MESENCHYMAL STEM CELL; MITOSIS INDEX; PREDICTIVE VALUE; PROGNOSIS; RUPTURE;

EID: 79960993686     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Liegl-Atzwanger B, Fletcher JA and Fletcher CD: Gastrointestinal stromal tumors. Virchows Arch 456: 111-127, 2010.
2. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol 33: 459-465, 2002. (Pubitemid 34747864)
3. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350): 577-580, 1998. (Pubitemid 28067289)
4. Huizinga JD, Thuneberg L, Kluppel M, et al: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512): 347-349, 1995.
5. Kindblom L, Ramotti H, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269, 1998. (Pubitemid 28221878)
6. Hubbard SR: Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 5: 464-471, 2004.
7. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.
8. Corless CL and Heinrich MC: Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557-586, 2008. (Pubitemid 351488293)
9. Lasota J and Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53: 245-266, 2008.
10. Lasota J, Corless CL, Heinrich MC, et al: Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Path 21: 476-484, 2008. (Pubitemid 351441037)
11. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA-activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003. (Pubitemid 36159485)
12. Lasota J, Stachura J and Miettinen M: GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86: 94-100, 2006. (Pubitemid 43250972)
13. Agaram NP, Wong GC, Guo T, et al: Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromos Cancer 47: 853-859, 2008.
14. Kawanowa K, Sakuma Y, Sakurai S, et al: High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol 37: 1527-1535, 2006. (Pubitemid 44792229)
15. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al: Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 128: 24-30, 2001. (Pubitemid 32655477)
16. Fukasawa T, Chong JM, Sakurai S, et al: Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 91: 1241-1249, 2000. (Pubitemid 32042358)
17. Bergmann F, Gunawan B, Hermanns B, et al: Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies. Verh Dtsch Ges Pathol 82: 275-278, 1998.
18. Nilsson B, Bumming P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103: 821-829, 2005.
19. Tryggvason G, Gislason HG, Magnusson MK, et al: Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117: 289-293, 2005.
20. DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58, 2000.
21. Agaimy A, Markl B, Arnholdt H, et al: Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch 455: 101-108, 2009.
22. Pauwels P, Debiec-Rychter M, Stul M, et al: Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment a potential diagnostic pitfall. Histopathology 47: 41-47, 2005. (Pubitemid 40978812)
23. Andersson J, Sihto H, Meis-Kindblom JM, et al: NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29: 1170-1176, 2005. (Pubitemid 41232989)
24. Miettinen M, Fetsch JF, Sobin LH, et al: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30: 90-96, 2006. (Pubitemid 43740214)
25. Miettinen M, Makhlouf H, Sobin LH, et al: Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30: 477-489, 2006. (Pubitemid 43740149)
26. Prakash S, Sarran L, Socci N, et al: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27: 179-187, 2005.
27. Isozaki K, Terris B, Belghiti J, et al: Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157: 1581-1585, 2000.
28. Beghini A, Tibiletti MG, Roversi G, et al: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92: 657-662, 2001. (Pubitemid 32735203)
29. Maeyama H, Hidaka E, Ota H, et al: Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120: 210-215, 2001. (Pubitemid 32061885)
30. Carney JA: Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74: 543-552, 1999.
31. Carney JA and Stratakis CA: Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108: 132-139, 2002.
32. Pasini B, McWhinney SR, Bei T, et al: Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1): 79-88, 2008. (Pubitemid 350284184)
33. West RB, Corless CL, Chen X, et al: The novel marker, DOGl, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165: 107-113, 2004. (Pubitemid 38821818)
34. Espinosa I, Lee CH, Kim MK, et al: A novel monoclonal antibody against DOGl is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32: 210-218, 2008. (Pubitemid 351172135)
35. Lee HE, Kim MA, Lee HS, et al: Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 61: 722-729, 2008. (Pubitemid 351859964)
36. Rossi G, Valli R, Bertolini F, et al: PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract Histopathology 46: 522-531, 2005.
37. Parkkila S, Lasota J, Fletcher JA, et al: Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23(5): 743-750, 2010.
38. Sarlomo-Rikala M and Miettinen M: Gastric schwannoma - a clinicopathological analysis of six cases. Histopathology 27: 355-360, 1995.
39. Carlson JW and Fletcher CD: Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 51: 509-514, 2007.
40. Miettinen M and Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83, 2006. (Pubitemid 44692418)